Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as PIPE-791 Dose B
PIPE-791 · 4 trials · 11 indications
The number of subjects with TEAEs will be summarized in each treatment arm and compared within each treatment period.
Number of participants with TEAEs
| Arm | Type | Description |
|---|---|---|
| PIPE-791 Dose A | EXPERIMENTAL | - |
| PIPE-791 Dose B | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Active followed by Placebo | EXPERIMENTAL | - |
| Placebo followed by Active | EXPERIMENTAL | - |
| Healthy volunteers, brain PET imaging | EXPERIMENTAL | - |
| Healthy volunteers, lung PET imaging | EXPERIMENTAL | - |
| Volunteers with PrMS | EXPERIMENTAL | - |
| Volunteers with IPF | EXPERIMENTAL | - |
| PIPE-791 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PIPE-791 Dose A | DRUG | Participants will receive a daily oral dose of PIPE-791 in tablet form |
| PIPE-791 Dose B | DRUG | Participants will receive a daily oral dose of PIPE-791 in tablet form |
| Placebo | DRUG | Participants will receive a daily oral dose of matching Placebo in tablet form |
| PIPE-791 | DRUG | PIPE-791 tablet, taken once daily for 4 weeks |
Key Inclusion Criteria: * Male or female ≥ 40 years of age at the time of Randomization. * A diagnosis of IPF within 7 years prior to Screening, based on the 2022 ATS/ERS/JRS/ALAT practice guideline as confirmed by the Investigator, and a centrally read screening HRCT consistent with usual intersti...
Top 15 of 17 competitors
PIPE-791 is an investigational small molecule drug developed by Contineum Therapeutics, Inc. (ticker CTNM). It is being studied for chronic osteoarthritis pain, idiopathic pulmonary fibrosis, and multiple sclerosis. PIPE-791 is not approved and remains in clinical development, with Phase 1 and Phase 2 studies conducted in multiple countries.
PIPE-791 targets LPA1, a receptor. By acting on this receptor, the small molecule is designed to interfere with LPA1-mediated signaling, which is the mechanism under investigation across the company's pain, fibrotic, and neuroinflammatory programs. Contineum Therapeutics is developing PIPE-791 as an oral small molecule therapeutic.
PIPE-791 is developed by Contineum Therapeutics, Inc., which trades under the ticker CTNM. The company is advancing the small molecule across chronic osteoarthritis pain, idiopathic pulmonary fibrosis, and multiple sclerosis indications, with clinical activity spanning Phase 1 and Phase 2 studies in the United States, United Kingdom, and other countries.
PIPE-791 is in Phase 1 development overall, with a Phase 2 study now recruiting in idiopathic pulmonary fibrosis. The Phase 1 program includes completed studies in chronic osteoarthritis pain, chronic low back pain, multiple sclerosis, and healthy volunteers. PIPE-791 is investigational and has not been approved by the FDA.
PIPE-791 has been studied in four trials. NCT07284459 is a recruiting Phase 2 study in idiopathic pulmonary fibrosis with 324 participants. Completed studies include NCT06810245 in chronic osteoarthritis pain and chronic low back pain, NCT06683612, a PET study in healthy volunteers and patients with multiple sclerosis and IPF, and NCT05983939, a Phase 1 dose-escalation and food-effect study.
PIPE-791 Dose A is an alternative name used for PIPE-791, the LPA1 receptor small molecule from Contineum Therapeutics. Both names refer to the same investigational asset being studied in chronic osteoarthritis pain, idiopathic pulmonary fibrosis, and multiple sclerosis. Searches for either name lead to the same clinical program.